Obs of a Prnnl Lrnr Obsrvr who happens to be a dctr
There is no cure for curiosity-D Parker
Saturday 8 June 2024
Fezolinetant, the first neurokinin receptor antagonist to receive approval from the FDA to treat vasomotor symptoms, may be an option for women concerned about hormone-based therapy for menopausal hot flashes.
A
Fezolinetant, the first neurokinin receptor antagonist to receive approval from the FDA to treat vasomotor symptoms, may be an option for women concerned about hormone-based therapy for menopausal hot flashes.
No comments:
Post a Comment